Skip to content
  • Global Key Solutions is now KeyPedia →
  • Use KeyPedia in Claude →
  • Global Key Solutions is now KeyPedia →
  • Use KeyPedia in Claude →
KeyPediaKeyPedia
  • Company
  • Platform
  • Media
  • KeyPedia Lite
Platform/Research

Open science, open evidence, open innovation.

Leading with frontier research

KeyPedia is built on peer-reviewed research published in leading pharmaceutical and regulatory science journals.

Publishing at the frontier of science and technology allows us at KeyPedia not only to develop innovative methods for data capture, statistical analysis, and ways of showcasing and demonstrating the impact and innovation of our research and data, but also to remain industry leaders, setting a benchmark for any and all who work on similar challenges and topics. By sharing with the world, we have the ability to collaborate in unprecedented manners at unprecedented speeds.

Our work, and the work of others and collaborators, has been featured from late night talk shows with millions of views to Senate committee hearings with deep political impact and appropriation dollars. We work to continue this precedent of innovation and work.

Papers

  1. 1.

    Artificial intelligence in FDA regulatory correspondence, 2022 to 2026: a retrospective document analysis

    George Kwiecinski, Reet Nandy (2026). Discover Pharmaceutical Sciences. https://doi.org/10.1007/s44395-026-00061-5

    Abstract

    This retrospective analysis searched the full text of all 3,011 FDA warning letters issued from January 2022 through September 2026 for references to artificial intelligence. Seven letters (0.23%) referred to AI: 3 device, 3 tobacco, and 1 drug. Only one, sent to Purolea Cosmetics Lab in April 2026, treated a firm's use of AI as a violation, citing AI-generated documents that lacked quality unit review under 21 CFR 211.22(c). One establishment inspection report and 2 Form FDA 483s also referred to AI.

  2. 2.

    The Foreign Inspection Gap: FDA GMP Oversight of U.S. Drug Imports, 2014–2024

    George Kwiecinski, Kevin Yuan (2026). Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-026-10406-3

    Abstract

    With the globalization of the pharmaceutical industry, the majority of active pharmaceutical ingredients and finished drug products entering the U.S. market originate from overseas manufacturing sites. From 2014 to 2024, FDA-conducted foreign Good Manufacturing Practice (GMP) inspections have fallen sharply. This study examines how trends in FDA inspection quality relate to increasing import volumes of drugs into the United States by analyzing FDA-issued observations since 2014. Increasing import volumes corresponded with declining inspection frequencies from 2014 to 2019. For every additional billion dollars of drug imports to the United States, there were 23 fewer inspections conducted during 2014–2019. The documented decline in inspection intensity, stable inspection outcome rates despite varying inspection volumes, and persistent disparities between MRA and non-MRA countries provide empirical support for the FDA's May 6, 2025, shift toward unannounced foreign inspections.

  3. 3.

    Regulatory Data Insights and Methods of Extraction and Analysis

    George Kwiecinski, Zephaniah Odidika (2025). PDA Journal of Pharmaceutical Science and Technology (Poster abstract). https://doi.org/10.5731/pdajpst.2025.25410

    Summary

    The PDA Week 2025 poster presents methods for extracting and analyzing regulatory records. This is a conference abstract accompanying the poster, rather than a separate full-length research article.

  4. 4.

    An Analysis of FDA Warning Letter Citations from 2019-2023

    George Kwiecinski (2024). Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-024-09879-x

    Abstract

    This study investigates trends in the issuance of FDA warning letters from 2019 to 2023. The paper aims to assess past and present FDA statements of inspection efficiency from a quantitative and qualitative perspective. An analytical approach combining regex filtering and web scraping was developed to log citations of law within FDA warning letters. The process included identifying recurring keywords for categorization by keyword, department, and legal reference. From 2019 to 2023, the FDA went from issuing a warning letter 2.98 times per 100 inspections to 4.27 times per 100 inspections, a 43% increase in warning letters issued per 100 inspections.

  5. 5.

    FDA drug quality assurance inspections: frequency, outcomes, and time to reinspection, 2008-2025

    Yunxiang Sun, Jeromie Ballreich, Joy Acha, Riya Modi, Mohammad Ali Alamdar Yazdi, Maqbool Dada, Tinglong Dai, Gerard Anderson, Mariana P. Socal (2026). Health Affairs Scholar. https://doi.org/10.1093/haschl/qxag229

    Summary

    Examines 25,629 FDA inspections and the timing of follow-up after different inspection outcomes. It extends the evidence on inspection activity through 2025.

  6. 6.

    The Price and Quality of Methylphenidate Products

    Aditya Narayan, Ben Teasdale, A.J. Hudspeth, David Y. Light, Jill K. Nailor, Kevin Schulman (2026). Journal of the American Academy of Child & Adolescent Psychiatry. https://doi.org/10.1016/j.jaac.2025.05.002

    Summary

    Examines dissolution and impurity differences among sampled methylphenidate products. The laboratory findings do not by themselves establish clinical differences between products.

  7. 7.

    Substandard Generic Drugs: Threats to Patient Safety and National Security

    Kevin Schulman, Arthur L. Kellermann (2026). New England Journal of Medicine (Perspective). https://doi.org/10.1056/NEJMp2518256

    Summary

    A perspective on generic-drug quality and national security.

  8. 8.

    Are All Generic Drugs Created Equal? An Empirical Analysis of Generic Drug Manufacturing Location and Serious Drug Adverse Events

    In Joon Noh, John Gray, George Ball, Zachary Wright, Hyunwoo Park (2025). Production and Operations Management. https://doi.org/10.1177/10591478251319691

    Summary

    Compares reported serious adverse events for equivalent generic drugs made in different locations. The findings are observational associations.

  9. 9.

    The Impact of Current Good Manufacturing Practices Inspections on Continuous Improvement Mindset in the Pharmaceutical Industry

    Matteo Bernasconi, Thomas Friedli, Oliver von Dzengelevski (2025). Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-025-10200-7

    Summary

    Uses manufacturing surveys, inspection records, and interviews to examine how inspections interact with quality-management practices and continuous improvement over time.

  10. 10.

    A Dynamic Model for GMP Compliance and Regulatory Science

    Yiyi Bao, Nicholas Buhay, Qiang Zheng (2024). Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-024-09825-x

    Abstract

    This research proposes a dynamic model designed to investigate the underlying principles of regulatory science and assess the effectiveness of pharmaceutical GMP regulation. A dynamic model for the state of compliance of a pharmaceutical manufacturing firm is constructed by using a generalized Ornstein-Uhlenbeck equation. The model is based on quantitative characterization of principles of proportionality, transparency and consistency, and regulatory effectiveness as measured by efficiency, cost and quality. The dynamic model is capable of characterizing a wide range of compliance behaviors and regulatory actions.

  11. 11.

    A Communication Effectiveness Study of the FDA GMP Warning Letters

    Yiyi Bao, Qiang Zheng (2024). Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-024-09844-8

    Abstract

    This study examines the structure and content trend over time of FDA GMP Warning Letters for their roles in effective communication. The structure and content trend over time of Warning Letters are studied using a combination of parsing text based on function, manual coloring and Python automation. The observed trends using these methods indicate that the content of suggestions on how to respond to a Warning Letter, for third party participation and further reading consistently increases over time. Warning Letters have become increasingly informative, showing FDA's good practice of transparency as a way to improve regulatory effectiveness.

  12. 12.

    Safety vs Price in the Generic Drug Market: Metformin

    Ben Teasdale et al. (2024). The American Journal of Managed Care. https://doi.org/10.37765/ajmc.2024.89450

    Summary

    Combines testing for NDMA and DMF in metformin with market data, examining post-recall quality and the relationship between contamination and price in the sampled products.

  13. 13.

    FDA Global Drug Inspections: Surveillance Of Manufacturing Establishments Remains Well Below Pre-COVID-19 Levels

    Emily Cuddy, Yun Peng Lu, David B. Ridley (2023). Health Affairs. https://doi.org/10.1377/hlthaff.2023.00686

    Summary

    Tracks domestic and foreign FDA drug inspections from 2012 through 2022, documenting the pandemic-related decline and examining changes in resources and inspection findings.

  14. 14.

    A data-driven quality-score system for rating drug products and its implications for the health care industry

    Arash Dabestani, Sara Grossman, Joseph P. Nathan, Carl W. Bazil, Ryan C. Costantino, Erin R. Fox, Joe Graedon, John V. Gray, Harry M. Lever, David Y. Light, Robert Makuch, Kevin A. Schulman, C. Michael White, Kenny Yu (2023). Journal of the American Pharmacists Association. https://doi.org/10.1016/j.japh.2022.10.001

    Summary

    Proposes a drug-quality score combining public regulatory information with independent chemical testing, and a workflow for considering quality alongside price in procurement. The article presents a framework, rather than validation of a specific commercial score.

  15. 15.

    The Reaction of Sponsor Stock Prices to Clinical Trial Outcomes: An Event Study Analysis

    Manish Singh, Roland Rocafort, Cathy Cai, Kien Wei Siah, Andrew W. Lo (2022). PLOS ONE. https://doi.org/10.1371/journal.pone.0272851

    Abstract

    We perform an event study analysis that quantifies the market reaction to clinical trial result announcements for 13,807 trials from 2000 to 2020, one of the largest event studies of clinical trials to date. We first determine the specific dates in the clinical trial process on which the greatest impact on the stock prices of their sponsor companies occur. We then analyze the relationship between the abnormal returns observed on these dates due to the clinical trial outcome and the properties of the trial, such as its phase, target accrual, design category, and disease and sponsor company type (biotechnology or pharmaceutical). We find that the classification of a company as 'early biotechnology' or 'big pharmaceutical' had the most impact on abnormal returns, followed by properties such as disease, outcome, the phase of the clinical trial, and target accrual.

  16. 16.

    FDA Warning Letters: A Retrospective Analysis of Letters Issued to Pharmaceutical Companies from 2010–2020

    Aakriti Rudra, Maninder Kaur (2022). Journal of Pharmaceutical Innovation. https://doi.org/10.1007/s12247-022-09678-2

    Abstract

    The present study examines the causes of warning letters issued by the Center for Drug Evaluation and Research (CDER), FDA to pharmaceutical companies after post-approval inspections. Warning letters issued from 2010 to 2020 were obtained from the FDA website, and information about date of issuance, company, and type of violations was extracted. Poor compliance to CGMP and misbranding were the most common reasons for the warning letters. Detailed analysis of CGMP warning letters elucidated three major types of violations: deficiencies in process validation, documentation practices (data integrity), and quality control, corresponding to 26%, 21%, and 15% of warning letters, respectively. The findings demonstrate that the FDA's major concern is CGMP compliance, and that pharmaceutical manufacturers need effective quality management systems governing the entire manufacturing process, quality control, employee training, and documentation practice.

  17. 17.

    Benchmarking the Quality Practices of Global Pharmaceutical Manufacturing to Advance Supply Chain Resilience

    Matt Fellows, Thomas Friedli, Ye Li, Jennifer Maguire, Nandini Rakala, Marten Ritz, Matteo Bernasconi, Mark Seiss, Neil Stiber, Mat Swatek, Alex Viehmann (2022). The AAPS Journal. https://doi.org/10.1208/s12248-022-00761-7

    Summary

    A voluntary study of more than 200 manufacturing establishments examines how selected quality-management practices relate to manufacturing and delivery performance.

  18. 18.

    Unpacking the Effects of Adverse Regulatory Events: Evidence from Pharmaceutical Relabeling

    Matthew J. Higgins, Xin Yan, Chirantan Chatterjee (2020). Research Policy. https://doi.org/10.1016/j.respol.2020.104132

    Abstract

    This study examines the impact of adverse regulatory events on pharmaceutical companies through the lens of drug relabeling. Using comprehensive data on FDA-mandated label changes, we analyze how these regulatory interventions affect firm value, innovation trajectories, and competitive dynamics in the pharmaceutical industry. Our findings reveal significant heterogeneity in firm responses based on company size, pipeline diversity, and the severity of the relabeling event. The research provides crucial insights into how regulatory actions shape pharmaceutical innovation and market structure, with implications for both policy makers and industry stakeholders.

  19. 19.

    Promoting Change from the Outside: Directing Managerial Attention in the Implementation of Environmental Improvements

    Suvrat Dhanorkar, Enno Siemsen, Kevin W. Linderman (2018). Management Science. https://doi.org/10.1287/mnsc.2017.2748

    Abstract

    Regulatory agencies, auditing firms, and supply chain partners externally promote change in firms, commonly employing two contradictory intervention approaches: punitive tactics to coerce firms to change and supportive tactics to encourage change. Using the context of government agencies promoting environmental improvements, we examine whether such punitive (e.g., regulatory inspections with possible sanctions) and supportive (e.g., environmental assistance, improvement recommendations) tactics can be administered in a complementary manner. Using a longitudinal data set from two state-level environmental agencies in Minnesota, we analyze over 1,000 supportive environmental improvement projects in combination with intermittent punitive tactics. The timing, severity, and relatedness of punitive tactics is critical for directing managerial attention and improving the efficacy of supportive tactics: contingent on timing, inspections can increase implementation rates by up to 60% but can also reduce them by up to 50%.

  20. 20.

    Colocation Still Matters: Conformance Quality and the Interdependence of R&D and Manufacturing in the Pharmaceutical Industry

    John V. Gray, Enno Siemsen, Gurneeta Vasudeva (2015). Management Science. https://doi.org/10.1287/mnsc.2014.2104

    Abstract

    This study investigates the conformance quality benefits of colocating manufacturing with research and development (R&D) activities. Findings from a panel data set of U.S.-based pharmaceutical plants over a 13-year period reveal that colocation of manufacturing and R&D relates to better conformance quality, on average, across the entire sample. These benefits of colocation persist throughout the 1994–2007 period, which is surprising given the rapid development of information and communication technologies during that time. The benefits are particularly enhanced for manufacturing plants operating with processes involving a high level of tacit process knowledge and that belong to large firms. The findings highlight the importance of matching organizational design with process and firm characteristics in settings involving knowledge interdependence, and the continued value of physical proximity between manufacturing and R&D activities to achieve desired quality outcomes.

  21. 21.

    The Influence of ISO 9000 Certification on Process Compliance

    John V. Gray, Gopesh Anand, Aleda V. Roth (2015). Production and Operations Management. https://doi.org/10.1111/poms.12252

    Abstract

    This article examines the influence of ISO 9000 certification on plant-level process compliance, arguably its first-order, targeted performance dimension. The empirical setting is the medical device manufacturing industry, with process compliance measured through FDA inspections of manufacturing plants. We control for several observable factors by matching certified plants with non-certified plants. Using longitudinal data, we find plants that obtained certification in the earlier diffusion period tend to have significantly better process compliance than a matched, non-certified control group, and the compliance difference is greater for early-certified plants than for late-certified plants. We also find deterioration in process compliance over time after certification. The study provides a useful baseline for assessing causality in ISO 9000–performance linkages and highlights the need for continued vigilance post certification.

  22. 22.

    Decay, Shock, and Renewal: Operational Routines and Process Entropy in the Pharmaceutical Industry

    Gopesh Anand, John V. Gray, Enno Siemsen (2012). Organization Science. https://doi.org/10.1287/orsc.1110.0709

    Abstract

    In this study, we examine decay in adherence to operational routines over time. Our empirical setting is the worldwide pharmaceutical industry, and we focus on operational routines used to maintain product quality. Based on an analysis of longitudinal data from U.S. Food and Drug Administration (FDA) inspections, we find that the tendency of operational routines to decay is widespread. Our results also illustrate that FDA inspections act as external renewals that halt decay in adherence to routines. In addition, manufacturing plants are found to vary significantly in their level of decay. Using data on mergers and acquisitions affecting these plants, we find that mergers appear to cause decay in adherence to routines, while acquisitions appear to serve as renewals and halt such decay.

KeyPedia
The intelligence layer for life sciences
Stay in the loop

KRA score changes, company updates and news. About monthly, unsubscribe anytime.

Contact
Quick Links
HomePlatformUse CasesHardwarePricingResearchOur TechnologyFAQMedia
KeyPedia™ Lite
Browse HubDatabase DirectoryRecordsCompaniesOfficesPeopleCareersAbout UsFounding TeamMeet Our ExpertsPrograms & Partnerships
Legal & Ethics
Privacy PolicyTerms of ServiceOur Values & MissionCode of Ethics & AI Policy
©2026 KeyPedia™ | Global Key Solutions Corp. All rights reserved.